– TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Everbright Digital Holding Limited Announces Closing of Initial Public Offering - April 21, 2025
- NorthEast Community Bancorp, Inc. Reports Results for the Three Months Ended March 31, 2025 - April 21, 2025
- OWNx Launches Industry-First “EDGE” Membership: Buy Gold, Silver, and Platinum At-Cost with Zero Fees - April 21, 2025
